The relation between dietary restriction or clenbuterol (a selective β2 agonist) treatment on muscle growth and calpain proteinase (EC3.4.22.17) and calpastatin activities in lambs

Abstract

1. Lamb growth trials were designed to modify growth and protein content of muscle by diet and also by β-agonist treatment, and to correlate any changes to the activities of calpain proteinases (EC3.4.22.17) and their inhibitor calpastatin.2. Wether lambs in a control group were fed on a barley-based diet designed to give a growth rate of 350 g/d; a second group was fed on the same diet but the intake was restricted to give an expected gain of 44 g/d; a third group was fed on the same diet as the first group but the diet included 2 mg clenbuterol/g. At the end of a 6-week trial, longissimus dorsi wet weights were 635 (n6), 377 (n4) and 788 g (n6) (standard error of difference 53.0) in the three groups respectively.3. Minced L. dorsi was extracted in low-salt buffers and analysed by a fast protein liquid-chromatographic system for calpain I (low calcium-requiring), calpain II (high Ca2+-requiring) and calpastatin activities. No significant changes in the three activities were associated with reduced muscle weight in the restricted-intake group. The inclusion of clenbuterol in the diet, however, led to highly significant increases (P< 0.001) in calpain II and calpastatin to approximately double the control values.4. The results did not support a direct relation between these activities and muscle growth, except when protein accretion was stimulated by a β-agonist, suggesting a role for this enzyme system in the mechanism by which these agents exert their effect.